ClinicalTrials.gg
Status unknownNCT03294343Updated Dec 26, 2017

Risk-Reducing Surgeries for Hereditary Ovarian Cancer

An interventional study of salpingo-oophorectomy only by laparoscopy and salpingo-oophorectomy with hysterectomy by laparoscopy in Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis and Ovariectomy, sponsored by Lei Li. Status unknown at 1 site in China. Open to female participants aged 35 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-26.

Sponsored by Lei Li · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Non-randomized
Ages
35 Years and older
Sex
Female
01

Study summary

Based on studies of "Inherited Susceptible Genes Among Epithelial Ovarian Cancer" (NCT03015376, clinicaltrials.gov) and "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer" (NCT03291106, clinicaltrials.gov), we provide risk-reducing surgeries of salpingo-oophorectomy with/without hysterectomy for healthy carriers with mutation genes of hereditary ovarian cancer, which is defined ovarian cancer with relevant pathogenic mutations.

02

Conditions studied

  • Hereditary Breast and Ovarian Cancer Syndrome
  • Colorectal Neoplasms, Hereditary Nonpolyposis
  • Ovariectomy
  • Hysterectomy
03

In context

Hereditary Breast and Ovarian Cancer Syndrome

62 studies on the registry are indexed under Hereditary Breast and Ovarian Cancer Syndrome; 13 are open to participants now.

This study's planned enrollment of 600 is above the median of 150 across 43 interventional studies indexed under Hereditary Breast and Ovarian Cancer Syndrome.

Browse Hereditary Breast and Ovarian Cancer Syndrome studies →

Lead sponsor

Lei Li is the lead sponsor of 62 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Carriers with known and definite mutation genes of hereditary ovarian cancer.
  • With children and without further requirement of pregnancy.
  • No less than 35 years for carriers with mutation gene of BRCA1.
  • No less than 40 years for carriers with mutation gene of BRCA2.
  • No less than 45 years for carriers with mutation genes of BRIP1, RAD51C, RAD51D and RAD51.
  • No less than 50 years for carriers with mutation genes of ATM, MSH2, MLH1, SH6, PMS2, EPCAM and STK11.

Exclusion criteria

Exclusion Criteria:

  • Without children.
  • Not reaching appreciate ages.
  • With of laparoscopy.
  • Refusal of risk-reducing surgeries.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    HBOCS

    For carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome), if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy only by laparoscopy and long-term follow-up are provided.

    Procedure: salpingo-oophorectomy only by laparoscopy

  • Experimental
    Lynch syndromes

    for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11, , if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy with hysterectomy by laparoscopy and long-term follow-up are provided.

    Procedure: salpingo-oophorectomy with hysterectomy by laparoscopy

  • Other
    Refusal to surgery

    For carriers with any mutation genes (BRCA1, BRCA2, ATM, BRIP1, RAD51, RAD51C, RAD51D, STK11, MLH1, MSH2, MSH6, PMS2 and EPCAM) but refusal to any risk-reducing surgeries, counseling, decision-making analysis, and then long-term follow-up are provided.

    Other: Follow-up

Interventions

  • Proceduresalpingo-oophorectomy only by laparoscopy

    Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.

  • Proceduresalpingo-oophorectomy with hysterectomy by laparoscopy

    Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.

  • OtherFollow-up

    Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries

06

What researchers measure

Primary outcomes

  1. Occult cancer or precancerous lesion in histological specimen

    Precancerous lesions include serous tubal intraepithelial carcinoma (STIC) and endometrial intraepithelial neoplasia (EIN)

    Time frame: 5 years

Secondary outcomes

  1. Overall survival

    Duration from surgery to death

    Time frame: 10 years

  2. Incidence of primary peritoneal carcinoma

    Incidence of primary peritoneal carcinoma after reception or refusal risk-reducing salpingo-oophorectomy

    Time frame: 10 years

  3. Incidence of primary uterine cancer

    Incidence of primary uterine cancer after reception or refusal risk-reducing hysterectomy

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
  • Lei Li
    Beijing, China/Beiing 100000, China
    Recruiting
    • Lei L Li, MD · Contactlileigh@163.com · 13911988831
    • Ming Wu, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Sep 2022, 60 months after the start.

Of 22 interventional studies with no phase under Hereditary Breast and Ovarian Cancer Syndrome, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31. This study's planned 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2017
First posted
Sep 27, 2017
StartActual
Sep 1, 2017
Primary completionEst.
Sep 1, 2022
CompletionEst.
Sep 1, 2023
Last update
Dec 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03294343
Lead sponsor
Lei Li
Responsible party
Lei Li (Professor, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Sep 27, 2017
Start date
Sep 1, 2017
Primary completion
Sep 1, 2022 (estimated)
Completion
Sep 1, 2023 (estimated)
Last update
Dec 26, 2017

Study contacts

Lei Li, MD
Contact
lileigh@163.com
13911988831 ext. +86
Lei Li, MD
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion